Natixis’s Burning Rock Biotech BNR Stock Holding History

Natixis’s Portfolio BNR Stock Details BNR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-4,929	Closed	-$458K	–	1164
2022 Q1	$458K	Sell	4,929 -336	-6%	-$29.2K	﹤0.01%	999
2021 Q4	$502K	Sell	5,265 -233	-4%	-$31.9K	﹤0.01%	1031
2021 Q3	$983K	Sell	5,498 -402	-7%	-$89.4K	﹤0.01%	896
2021 Q2	$1.74M	Sell	5,900 -98	-2%	-$29K	0.01%	546
2021 Q1	$1.61M	Buy	+5,998	New	+$1.83M	0.01%	744

Other funds holding BNR

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Natixis's BNR Position: Q2 2022 in Review

Natixis sold out of Burning Rock Biotech (BNR) in Q2 2022, closing a stake of 4,929 shares — an estimated $458K sold.

Natixis first reported a position in BNR in Q1 2021 and held it in 5 quarters. The position peaked at $1.74M in Q2 2021. 50 funds tracked by Wall St. Rank hold BNR as of Q2 2022.

Natixis reported no remaining Burning Rock Biotech position as of Q2 2022 after selling out during the quarter.
Natixis sold 4,929 Burning Rock Biotech shares in Q2 2022, an estimated $458K.
Natixis first reported a position in Burning Rock Biotech in Q1 2021 and held it in 5 quarters.
Natixis's Burning Rock Biotech position peaked at $1.74M in Q2 2021.
50 funds tracked by Wall St. Rank held Burning Rock Biotech as of Q2 2022.

Based on Natixis's 13F filing for Q2 2022, filed 12 Aug 2022.